State-owned Misr Life Insurance Company, Egypt's biggest life insurer, will offer 15% of its shares in an initial public offering on the Egyptian Exchange, subject to obtaining the necessary regulatory approvals and the suitability of market conditions.
The Board of Directors of Tawuniya, which is one of the biggest insurers in Saudi Arabia, has approved the appointment of Mr Sulaiman bin Abdulrahman Al-Gwaiz as Chairman and a Non-Executive Member of the Board.
South Korean healthcare providers and pharmacies risk carrying KRW900bn ($675m) in unsettled national health insurance claims into next year, according to the Korea Biomedical Review.
Swiss Re Institute forecasts global non-life premiums to grow by 1.0% in real terms in 2027 and 2.0% in 2028, while life insurance premiums are forecast to increase by 2.1% annually over 2027 and 2028.
SCOR has appointed Mr Adrian Kerins as Head of Life and Health (L&H), Australia and New Zealand (ANZ).
The Insurers Federation of Egypt (IFE) will launch new initiatives and programmes in the coming period to foster the development of the insurance industry, said Mr Alaa El-Zoheiry, IFE Chairman, at the opening of the 8th Sharm Rendezvous yesterday.
The UAE listed insurance industry saw net profit for the industry increase by 13% to AED3.2bn [$871.3m] for the first nine months of this year (9M2026) from AED2.8bn for the corresponding period of 2025), according to BADRI Management Consultancy, an international actuarial and risk management consulting firm.
Manulife Hong Kong has introduced the Spectrum Universal Life Insurance Plan, a Class A long-term policy that offers lifelong cover alongside a growth account or a fixed account.
Moody's Ratings new report examining how Japan's new economic capital regime is reshaping life insurers' capital and risk management reveals no significant direct impact on rated life insurers' capitalisation from the Japan Insurance Capital Standard (J-ICS), which was implemented at the end of March 2026.
China has updated the list of drugs available under its national medical insurance drug list and the commercial insurance innovative drug list. The commercial insurance innovative drug list was introduced in December 2025.